Sharing Resources:

Panel discussion on moving from research into clinical care

Chair: Kathryn North **Speakers**: Sue Hill, Peter Goodhand, Anna Middleton, Clara Gaff, Heidi Rehm, Zornitza Stark



The world is changing



Percentage of whole genomes and exomes that are funded by **healthcare** systems



Areas of clinical uptake: infectious disease, cancer, rare disease, common/chronic

How big is healthcare - worldwide



MRI – (\$400-\$4,000) 100 million scans - pa

PET/SPECT (\$1000-\$6,000) 50 million scans - pa



Opportunities



If we can enable secondary use of clinical genomic data for research we will have a >60 million virtual cohort by 2025.

Global genomic data sharing can lead to...

- Demonstrated patterns in health and disease
- Increased statistical significance of analyses
- Matching other / similar patients, leading to increased diagnoses
- 'Stronger' variant interpretations
- More informed clinical decisions





150+ Genomic Data Initiatives Globally









CLINICAL/GENOMIC MEDICINE



initiatives

RESEARCH



initiatives

NATIONAL



from 15 countries

COHORTS



globally

HTA – Government decision making



- Geisinger/Regeneron fund exomes and evaluate in practice
- Kaiser Permanente very diligent HTA pre introduction
- Canadian clinical genomes for RD diagnosis or large panels for cancer
 - Several provinces re-patriate "out-of-country tests" optics vs budget control; secondary use for research versus rather than pdf report; build the competency and capacity in hospital labs versus cost, speed, clinical certification; over capacity in research sequencing but lab not certified for clinical use
 - Other provinces no experience with clinical NGS- only research experience; ministries of health need clear, well articulated case with HTA that they will regard as valid and the competency/capacity – Pop scale 8.5 m vs ~1m or <
 - Work force, wait list, diagnostic odyssey, early identification, role of AI

Five times the diagnosis, one quarter the cost

ORIGINAL RESEARCH ARTICLE Genetics

A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders

D American Collines of Medical Genetics and Generation

Ø American College of Medical Genetics and Genomi

© American College of Medical Genetics and Genomics

Zernitza Stark, MD; Tiong Y. Tan, MD, PhD¹², Belinda Chong, PhD¹, Gemma R, Brett, MSC, MGenCours³⁵, Patrick Yao, MD¹, Male Walsh, MD¹Alison Yeung, MD¹, Heldi Peters, MD, PhD¹²⁴, Dylan Mordaunt, MD¹²⁴, Shamon Cowle, BSC; David J. Amor, MD, PhD¹²⁴, Favi Savarirayan, MD¹²⁴, George McGillivray, MD¹, Lilian Downie, MD, Paul G. Extr, MD, PhD¹²⁴, Christiane Theeda, MD, PhD¹²⁴, Paul A. James, MD, PhD¹, Joy Yapito Lee, MD¹²⁴, Monique M, Ryan, MD¹²⁴, Richard J. Leventer, MD, PhD¹²⁴, Pama Creed, MGenCours²⁴⁶, Iwan Macciocca, BSC, MHSci, Katrina M. Bell, PhD¹²⁴, Izmara Check, PhD¹²⁴, Monique M, Ryao, BEng¹, Peter Georgeson, BEng, BMath², Charlotte Andrearon, BSC, Mitse¹, Stasian M White, MD¹²⁴

ORIGINAL RESEARCH ARTICLE Genetics in Medicine

Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement

Zornitza Stark, MD¹, Deborah Schofield, PhD^{13,4}, Khurshid Alam, PhD¹⁴, William Wilson, PhD¹⁶, Nessie Mupfeki, MHIM¹⁵, Ivan Macciocca, MHSc¹⁵, Rupendra Shrestha, PhD², Susan M. White, MD¹⁴⁵ and Clara Gaff, PhD¹⁵

ARTICLE Genetics

Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness

Zornitza Stark, BMBCh DM¹⁻²³, Deborah Schofield, PhD^{14,5}, Melissa Martyn, PhD²³, Luke Rynehart, BEcon¹, Rupendra Shrestha, PhD¹, Khurshid Alam, PhD^{13,6}, Sebastian Lunke, PhD¹, Tiong Y, Tan, MBS PhD^{1,23}, Clara L. Gaff, PhD²³ and Susan M. White, MBS^{1,3}

Prospective comparison of diagnosis

- 80 children <2 years of age
- Features of known mendelian conditions
- 58% diagnosis vs 11% in standard care

Cost effectiveness study of first 40 children

- Cost per diagnosis \$5047 vs \$27050 std care
- Incremental saving of \$2,181 per additional dx

enomics

65

Bootstrapped & sensitivity analysis

Follow up cost utility study

- Cost saving of AU\$1,578 per QALY gained
- No increase in hospital service use.

Melbourne Genomics Health Alliance

Design Gaff et al, (2017) npj Genomic Medicine 2: Article 16

Evaluation for effective education

Genetic specialists: Current practice and workforce



Other medical specialists: needs, practice, preference



Surveying medical specialists about their practice and training in genomics

Information and consent to participate

This survey is an activity of the Workshore & Education Program of the Australian Genomics Health Allance (Australian Genomics) and a Healthan Charlon and the Healthan Genomics). The automatical frequency is and the automatical frequency and the

Tools to assist genomic education design and evaluation









Research Topic


Educating Health Professionals in Genomic Medicine: Evidence-

Based Strategies and Approaches

Program logic + evaluation framework for genomic education







Making the case for genomics



COST/BENEFIT

- Understanding cost of multiple sequential testing/ unwarranted variation & establishing activity
- Replacement of outmoded technologies – enhanced diagnostic yield above SoC
- Made clinical & economic case for both non-WGS & 500K WGS in mainstream care & mechanism for annual review & prioritisation
- Gained tripling of investment in genomics over next 5 years & centralisation of budgets


QUALITY & OUTCOMES

- Improving care in key national clinical priority areas (Cancer/ Rare Disease/CVD/Acute Care)
- Supporting and linking with personalisation/ medicines optimisation & ADR reduction (NHS drugs budget £17bn pa)
- Established principle & buy in for single national approach, protocols, standards, datasets, data sharing, IG, metrics & scrutiny (quality dashboard) *inc National Genomics Testing Service & National Genomics Test Directory*

DELIVERY & SERVICE MODEL

- Established WGS deliverability and requirements for whole infrastructure (inc non-WGS) with NHS informatics and data developments
- Service & human cost of diagnostic odyssey
- Reducing inequity and unmet clinical need
- Demonstrated value of new models of care and how existing services could be consolidated & networked

The new national genomic infrastructure



Developing the health system workforce alongside service transformation



The Genomics Education Programme was established in 2014 to run alongside the developments in genomic medicine services to driving training and upskilling for the **entire 1.3 million NHS** workforce

The GEP provides a wide range of free-to-access resources to provide an **'anytime**, **anyplace**, **anywhere'** approach to education – tailored to suit the range of professional requirements, the extent and time available for learning & the immediate need for education

Central to the programme is the multiprofessional **Masters in Genomic Medicine** (& associated CPD modules) and specialist commissioned training places (eg Bioinformatics & genomic counselling) + undergraduate & postgraduate training curricula



Resources and material at genomicseducation.hee.nhs.uk and www.futurelearn.com

Resources show huge reach

50,000+ total staff reached

1400+ Masters framework places
1.5million+ web page views
460,000+ resource views
34,440 course registrations
19,600+ MOOC registrations Public Engagement

Prof Anna Middleton Wellcome Genome Campus, Cambridge, UK www.wgc.org.uk/ethics

Public engagement is **not** education

It is:

Making a connection, Building a bridge No scientific jargon, but culturally acceptable metaphors

Different engagement for publics and patients


We already have 50+ GA4GH films on genomic data sharing, translated into 14 languages, plus 20 other films in English (incidental findings, genetic counselling terms etc)



Light touch, google search as a metaphor for sequencing

Prof Anna Middleton Wellcome Genome Campus, Cambridge, UK www.wgc.org.uk/ethics

(Click on image to open video in YouTube)



















Deeper connection, dominant inheritance, used within clinic

Prof Anna Middleton Wellcome Genome Campus, Cambridge, UK www.wgc.org.uk/ethics



(Click on image to open video in YouTube)















